Adjuvant Hysterectomy in Patients After Radiation for Locally Advanced Cervical Cancer: A Single-Center Prospective Longitudinal Study

Overview

Journal J Obstet Gynaecol India

Specialty Gynecology & Obstetrics

Date 2024 Sep 16

PMID 39280208

Authors

Sony Nanda

Bhagyalaxmi Nayak

S N Senapati

A K Padhy

Mamita Nayak

Jita Parija

Janmejaya Mohapatra

Manoranjan Mahapatra

Affiliations

Soon will be listed here.

Abstract

Introduction: Residual or recurrent cervical cancer post-CCRT is a challenging clinical issue, even though there has been much effort in recent decades to increase patient survival after radiation. There is a paucity of literature regarding the role of hysterectomy in recurrent/residual disease after radiation in LACC patients. Such a procedure is controversial and not routinely performed because of difficulties in obtaining tumor-free margins and the high rate of associated morbidity.

Aims And Objectives: Evaluate outcomes and morbidities in patients who had undergone hysterectomy for residual or recurrent disease after radiation in LACC patients.

Material And Methods: This is a prospective observational study on radiotherapy-treated LACC patients (IIB-III) with residual disease or recurrent disease who have undergone adjuvant hysterectomy. This study has been conducted at AHPGIC, Cuttack, with a sample size of 30 patients.

Results: 18/30 patients underwent extrafascial hysterectomy, and rest 12 patients had radical hysterectomy. No significant difference in complications, achieving tumor free margins or recurrences post adjuvant hysterectomy based on the radicality of surgery was observed. 5 cases of recurrences post-adjuvant hysterectomy were detected. Some of the factors which had significant association with recurrences post adjuvant hysterectomy were non squamous histology, no preoperative brachytherapy, deep stromal invasion and positive surgical margins. Median follow-up time was 14 months (12-27 months).

Conclusion: This study shows that adjuvant hysterectomy is feasible with good outcome and acceptable morbidity after chemoradiotherapy in cervical cancer patients "

References

Monk B, Tewari K . Evidence-based therapy for recurrent cervical cancer. J Clin Oncol. 2014; 32(25):2687-90. DOI: 10.1200/JCO.2014.56.8733. View

Boers A, Arts H, Klip H, Nijhuis E, Pras E, Hollema H . Radical surgery in patients with residual disease after (chemo)radiation for cervical cancer. Int J Gynecol Cancer. 2014; 24(7):1276-85. DOI: 10.1097/IGC.0000000000000171. View

Ebina Y, Mikami M, Nagase S, Tabata T, Kaneuchi M, Tashiro H . Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. Int J Clin Oncol. 2018; 24(1):1-19. DOI: 10.1007/s10147-018-1351-y. View

Datta N, Stutz E, Gomez S, Bodis S . Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Int J Radiat Oncol Biol Phys. 2018; 103(2):411-437. DOI: 10.1016/j.ijrobp.2018.09.037. View

Pergialiotis V, Bellos I, Douligeris A, Thomakos N, Rodolakis A, Haidopoulos D . The impact of adjuvant hysterectomy on survival outcomes of patients with locally advanced cervical cancer: A network meta-analysis. Eur J Surg Oncol. 2021; 48(1):261-267. DOI: 10.1016/j.ejso.2021.09.008. View

Nasioudis D, Latif N, Giuntoli Ii R, Haggerty A, Cory L, Kim S . Role of adjuvant radiation therapy after radical hysterectomy in patients with stage IB cervical carcinoma and intermediate risk factors. Int J Gynecol Cancer. 2021; 31(6):829-834. DOI: 10.1136/ijgc-2021-002489. View

Tewari K, Sill M, Long 3rd H, Penson R, Huang H, Ramondetta L . Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370(8):734-43. PMC: 4010094. DOI: 10.1056/NEJMoa1309748. View

Cagetti L, Zemmour C, Minsat M, Lambaudie E, Houvenaeghel G, Provansal M . Lessons from radiochemotherapy and modern image-guided adaptive brachytherapy followed by hysterectomy. Gynecol Oncol. 2019; 156(2):328-334. DOI: 10.1016/j.ygyno.2019.12.001. View

Miller H, Matsuo K, Roman L, Yessaian A, Pham H, Hom M . Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery. Radiat Oncol. 2021; 16(1):123. PMC: 8244186. DOI: 10.1186/s13014-021-01843-0. View

10.

Ota T, Takeshima N, Tabata T, Hasumi K, Takizawa K . Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy. Br J Cancer. 2008; 99(8):1216-20. PMC: 2570512. DOI: 10.1038/sj.bjc.6604619. View

11.

Pervin S, Ruma F, Rahman K, Ferdous J, Ara R, Abu Syed M . Adjuvant Hysterectomy in Patients With Residual Disease After Radiation for Locally Advanced Cervical Cancer: A Prospective Longitudinal Study. J Glob Oncol. 2019; 5:1-7. PMC: 6426523. DOI: 10.1200/JGO.18.00157. View

12.

Mabuchi S, Isohashi F, Yoshioka Y, Temma K, Takeda T, Yamamoto T . Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer. 2010; 20(5):834-40. DOI: 10.1111/IGC.0b013e3181dcadd1. View

13.

Souza E, Santos D, Torres J, Vale D, Braganca J, Teixeira J . Post-radiotherapy hysterectomy does not benefit females with cervical adenocarcinoma. Mol Clin Oncol. 2020; 13(6):92. PMC: 7657080. DOI: 10.3892/mco.2020.2162. View

14.

Walji N, Chue A, Yap C, Rogers L, El-Modir A, Chan K . Is there a role for adjuvant hysterectomy after suboptimal concurrent chemoradiation in cervical carcinoma?. Clin Oncol (R Coll Radiol). 2010; 22(2):140-6. DOI: 10.1016/j.clon.2009.11.006. View